HK1205788A1 - Elevated psma identifies lethal prostate cancers - Google Patents

Elevated psma identifies lethal prostate cancers Download PDF

Info

Publication number
HK1205788A1
HK1205788A1 HK15106199.9A HK15106199A HK1205788A1 HK 1205788 A1 HK1205788 A1 HK 1205788A1 HK 15106199 A HK15106199 A HK 15106199A HK 1205788 A1 HK1205788 A1 HK 1205788A1
Authority
HK
Hong Kong
Prior art keywords
adenocarcinomas
psma
lethal
identifies
tumors
Prior art date
Application number
HK15106199.9A
Other languages
English (en)
Chinese (zh)
Inventor
Neil H. Bander
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of HK1205788A1 publication Critical patent/HK1205788A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
HK15106199.9A 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers HK1205788A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602900P 2012-02-24 2012-02-24
US61/602,900 2012-02-24
PCT/US2013/000045 WO2013126147A2 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Publications (1)

Publication Number Publication Date
HK1205788A1 true HK1205788A1 (en) 2015-12-24

Family

ID=49003541

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106199.9A HK1205788A1 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Country Status (6)

Country Link
US (2) US20130225541A1 (https=)
EP (2) EP2817629A4 (https=)
JP (2) JP6501524B2 (https=)
CA (1) CA2865282A1 (https=)
HK (1) HK1205788A1 (https=)
WO (1) WO2013126147A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013130177A1 (en) * 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
AU2017348111B2 (en) * 2016-10-27 2023-04-06 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
EP4597424A3 (en) 2019-01-07 2025-10-29 Exini Diagnostics AB Systems and methods for platform agnostic whole body image segmentation
BR112021021011A2 (pt) 2019-04-24 2021-12-14 Exini Diagnostics Ab Sistemas e métodos para análise automatizada e interativa de imagens de varredura óssea para detecção de metástases
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
BR112022019335A2 (pt) 2020-03-26 2022-11-29 Marigdalia Kaleth Ramirez Fort Método para determinar uma quantidade de energia a ser entregue para provocar um efeito final em uma entidade invasiva-alvo de um alvo em um hospedeiro, método para fornecer terapia a um alvo com o uso de um dispositivo inteligente, método para monitorar um paciente exposto a um carcinógeno conhecido em um evento de exposição, método para tratar adaptativamente um volume de células com irradiação eletromagnética, método para medir a dose absorvida de energia entregue por meio de um alvo dentro de um volume de células, método para permitir regulação ascendente de depravação de androgênio, método para otimizar a dose absorvida de irradiação eletromagnética entregue por meio de um alvo dentro de um volume de células, sistema de terapia para um apêndice de paciente e sistema de terapia para uma cavidade de paciente
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
CA3231578A1 (en) 2021-10-08 2023-04-13 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE337011T1 (de) * 2001-02-07 2006-09-15 Beth Israel Hospital Modifizierte psma-liganden und deren verwendung
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
ATE408712T1 (de) * 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
WO2005021709A2 (en) * 2003-05-29 2005-03-10 Diadexus, Inc. Cln101 antibodies
JP2010507645A (ja) * 2006-10-25 2010-03-11 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 前立腺癌を検出するための造影剤
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
WO2010107909A2 (en) * 2009-03-17 2010-09-23 The Johns Hopkins University Methods and compositions for the detection of cancer

Also Published As

Publication number Publication date
CA2865282A1 (en) 2013-08-29
EP2817629A2 (en) 2014-12-31
WO2013126147A3 (en) 2014-12-24
WO2013126147A2 (en) 2013-08-29
US20130225541A1 (en) 2013-08-29
JP2019144254A (ja) 2019-08-29
US20180088120A1 (en) 2018-03-29
JP2015513083A (ja) 2015-04-30
EP2817629A4 (en) 2016-01-13
EP3064945A1 (en) 2016-09-07
JP6501524B2 (ja) 2019-04-17

Similar Documents

Publication Publication Date Title
HK1205788A1 (en) Elevated psma identifies lethal prostate cancers
Jeronimo et al. Epigenetic biomarkers in urological tumors: A systematic review
WO2019028285A3 (en) Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
WO2015017537A3 (en) Colorectal cancer recurrence gene expression signature
HK1219763A1 (zh) 用於癌症预後的组合物和方法
WO2011139721A8 (en) Cancer biomarkers and methods of use thereof
WO2014144121A3 (en) Classification and actionability indices for lung cancer
HK1255533A1 (zh) 用於检测大肠癌及进阶性腺瘤的蛋白质生物标志物面板
WO2016172710A3 (en) Methods and reagents for determination and treatment of organotropic metastasis
EA201401096A1 (ru) Комбинационная терапия, включающая антигиалуронановый агент и таксан, направленный на раковую мишень
WO2014153056A3 (en) Cancer treatment using antibodies that bing cell surface grp78
EP3290082A3 (en) Methods and devices for stimulating an immune response using nanosecond pulsed electric fields
HK1217375A1 (zh) 结果跟踪与分析的系统和方法
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EP4524569A3 (en) Methods, compositions and devices for treating cancer with illudofulvenes
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2017006609A (es) Aditivo de nanocristales de celulosa o nanofibrillas de celulosa modificadas de forma quimica.
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
HK1220253A1 (zh) 诊断前列腺癌症的方法
WO2018046770A3 (en) Marker and target as a diagnostic variable and target for therapy of metastatic cancer
EP3033150A4 (en) Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
WO2014205132A3 (en) Methods and compositions to treat cancer
WO2014107718A3 (en) Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
WO2013049398A3 (en) Protein-protein interaction as biomarkers
ES2672989T3 (es) FALZ para su uso como diana para terapias para tratar el cáncer